Obu Biology (300357.SZ): Currently, the stem cell drug being developed by the company's subsidiary is in the preclinical research stage, and it is impossible to predict the time of industrialization

Gelonghui, May 10 | Our Wu Biology (300357.SZ) said on the investor interactive platform that the indications for stem cell drug research projects can be reviewed in advance. Furthermore, innovative drug development has the characteristics of long cycle, large investment, and high uncertainty. Currently, stem cell drugs being developed by the company's subsidiaries are in the preclinical research stage, and it is impossible to predict the time for industrialization.

Gelonghui FinanceMay 10 18:41

Express News | Wawu Biotech: Stem cell drug research projects do not cover diabetes-related indications

BreakingsMay 10 10:31

Waku Biotech (300357.SZ): Does not involve diabetes-related indications

Gelonghui, May 9丨Our Wu Biology (300357.SZ) said on the investor interactive platform that the company's subsidiary's stem cell drug research project is currently in the preclinical research stage and does not involve diabetes-related indications.

Gelonghui FinanceMay 9 16:23

Wawu Biotech (300357): Revenue accelerated in the first quarter

Incident: The company released its 2023 report and 2024 quarterly report. In 2023, it achieved revenue of 850 million yuan (-5.3%), net profit to mother of 310 million yuan (-11.1%), and net profit of 300 million yuan (-5.2%) after deducting non-return to mother net profit of 300 million yuan (-5.2%)

西南證券Apr 28 00:00

We Wu Biology (300357): The low level of in-hospital promotion is over, and we expect new patients to gradually recover

Incident: The company released its 2023 annual report, achieving operating income of 848 million yuan (-5.34%), net profit to mother of 310 million yuan (-11.06%), and net profit of non-return to mother of 298 million yuan (-5.20)

海通證券Apr 26 16:51

Wawu Biology (300357): Artemisia artemisia drops are quickly dosed to gradually expand the variety of prickly products

Incident: The company disclosed the 2023 annual report and the 2024 quarterly report. In 2023, it achieved revenue of 848 million yuan, a decrease of 5.34%, and net profit to mother of 310 million yuan, a year-on-year decrease of 11.06%.

國聯證券Apr 22 16:01